Nephrocalcinosis Clinical Trial
Preterm infants are at risk to develop nephrocalcinosis. Incidence numbers vary according to birth weight and gestation age. Very low birth weight infants have the highest risk index, with ~ 7-10 % of preterm infants developing nephrocalcinosis in the patient population. We, the researchers at the University of Cologne, and others found significantly decreased urinary citrate excretion (hypocitraturia) to be one of the main risk factors. Hence, we hypothesized, that prophylactic treatment with oral alkaline citrate solution (Shol's solution) would help to 1) increase urinary citrate excretion and 2) help to decrease the incidence of nephrocalcinosis.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00875823 -
International Registry for Primary Hyperoxaluria
|
N/A | |
| Completed |
NCT04382976 -
The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm Infants
|
||
| Recruiting |
NCT00169806 -
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
|
N/A | |
| Not yet recruiting |
NCT05862207 -
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital
|
||
| Not yet recruiting |
NCT01756547 -
Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature
|
Phase 3 | |
| Active, not recruiting |
NCT04495608 -
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels
|
Phase 2 | |
| Completed |
NCT02438267 -
Preterm Infants and Nephrocalcinosis
|
N/A |